Fundraising Fox
/Companies
Sign in

Mediar Therapeutics

Boston, US · Founded 2018 · Delaware corporation · 58 employees on LinkedIn · 11 known investors

Find your way into Mediar Therapeutics

1,870 people in our graph share verified history with the Mediar Therapeutics team — schools, employers, funds. One of them is your warm intro.

Richard Heymanunlockedknows Rahul Ballal · together at Enliven Therapeutics (overlapped)
knows the team · via Enliven Therapeutics
knows the team · via Agios Pharmaceuticals
×9knows the team · via Versant Ventures

Mediartx develops novel therapies for patients with fibrotic diseases.

BiotechMedical Devices

Founders & leadership

RB
Rahul Ballal, PhDCEO
PYPaul Yaworsky, PhD
Paul Yaworsky, PhDCSOVenture Partner at RA Capital
RBRahul Ballal
Rahul BallalCEORahul Ballal is a biotech executive with over 15 years of experience in building companies and financing. He previously served as president and CEO of Imara, guiding the company from Series A through its IPO and merger with Enliven Therapeutics, and held prior roles including chief business officer at Northern Biologics, vice president of business development at Flexion Therapeutics, and entrepreneur-in-residence at Versant Ventures. He holds a Ph.D. in biochemistry from Georgetown University, an M.S. in bioinformatics from Johns Hopkins University, and a B.S. in biology from Brown University.
BH
Brian HubbardNamed on SEC filing
SB
Stacey BrennerNamed on SEC filing
DD
David de GraafNamed on SEC filing

Board

MB
Michael BaranBoard director
MFMeredith Fisher
Meredith FisherCo-founding CEO and Director2019–2023General Partner at Mass General Brigham Ventures
AJAndreas Jurgeit
Andreas JurgeitBoard MemberPartner at Gimv
AKAnja Konig
Anja KonigBoard Director2023–2025Global Head of NVF at Novartis Venture Fund
CBCassidy Blundell
Cassidy BlundellBoard directorPartner at Mission Biocapital
MBMaina Bhaman
Maina BhamanBoard directorPartner at Sofinnova Partners

Investors · 11

Gimvlisted by GimvAntwerp · $20M – $400M

How we know: Gimv's portfolio page · Not right? Tell us

Longwood Fundlisted by Longwood FundBoston

How we know: Longwood Fund's portfolio page · funding news · press coverage · the VCSheet dataset · Not right? Tell us

Mission Biocapitallisted by Mission BiocapitalSan Francisco · $500K

How we know: Mission Biocapital's portfolio page · funding news · the VCSheet dataset · Not right? Tell us

Novartis Venture Fundlisted by Novartis Venture FundBasel · $5M – $25Mvia Anja Koenig · board

How we know: Novartis Venture Fund's portfolio page · board seat on SEC Form D · funding news · Not right? Tell us

Ono Venture Investment, Inc.listed by Ono Venture Investment, Inc.South San Francisco

How we know: Ono Venture Investment, Inc.'s portfolio page · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us

ShangBay Capital LLClisted by ShangBay Capital LLCPalo Alto

How we know: ShangBay Capital LLC's portfolio page · Not right? Tell us

Sofinnova Partnerslisted by Sofinnova PartnersParis · $540K – $27Mvia Maina Bhaman · board

How we know: Sofinnova Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · Not right? Tell us

Amplitude Venture CapitalreportedMontreal

How we know: a partner's Signal profile · Not right? Tell us

Pfizer Venturesreported

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

$203.9M disclosed across 4 rounds · 2019–2026

▶$37.8MraisedDec 2025 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andreas JurgeitDirector
  • Bharat SrinivasaDirector
  • Allan MarchingtonDirector
  • Rahul BallalExecutive Officer, Director
  • Cassidy BlundellDirector
  • Maina BhamanDirector
  • Adam CottonDirector
  • Simon SturgeDirector
  • Marie-Claire PeakmanDirector
Offering amount
$75.7M
Amount sold
$37.8M
First sale
Dec 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$85MraisedOct 2024 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Simon SturgeDirector
  • Michael BaranDirector
  • Meredith FisherDirector
  • Andreas JurgeitDirector
  • Anja KonigDirector
  • Rahul BallalExecutive Officer, Director
  • Cassidy BlundellDirector
  • Maina BhamanDirector
Offering amount
$85M
Amount sold
$85M
First sale
Nov 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedFeb 2019 · 7 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian HubbardDirector
  • Stacey BrennerExecutive Officer
  • Peter ParkerDirector
  • David de GraafDirector
  • Meredith FisherDirector
Offering amount
$10M
Amount sold
$5M
First sale
Jan 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

3 people who came through Mediar Therapeutics went on to found or lead other companies.

Adam CottonBoard DirectorFounded Epi BiologicsRobert DrakasBoard ObserverFounded Rila TherapeuticsBharat SrinivasaBoard DirectorFounded Radiant Biotherapeutics

Related companies · 2

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Mozart TherapeuticsMozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments. The company is founded on research from Stanford University scientists and is led by experienced biopharmaceutical industry executives.

Companies working in the same space as Mediar Therapeutics.

In the news

Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolioprnewswire.com · Jan 2026News - Mediar Therapeuticsmediartx.com · Apr 2023Mediar raises $105 million to target fibrotic mediators - Mediar Therapeuticsmediartx.com · Mar 2023Mediar Therapeutics Raises $105M in Fundingfinsmes.com · Mar 2023

Frequently asked questions

What does Mediar Therapeutics do?
Mediartx develops novel therapies for patients with fibrotic diseases.
Who are Mediar Therapeutics's investors?
Mediar Therapeutics's investors include Agent Capital, Gimv, Longwood Fund, Mission Biocapital, Novartis Venture Fund, Ono Venture Investment, Inc., Pfizer Venture Investments, ShangBay Capital LLC and 3 more.
How much funding has Mediar Therapeutics raised?
Mediar Therapeutics has disclosed $203.9M raised across 4 rounds.
Where is Mediar Therapeutics headquartered?
Mediar Therapeutics is headquartered in Boston, US.